Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Polyphor
Polyphor
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Research & Development
Polyphor and Wellcome Trust to develop novel antibiotics against multi-drug resistant Gram-negative pathogens
Final milestone reached ahead of schedule triggering payment of a CHF 0.97 million convertible loan amount
Research & Development
Kalina Scott appointed new CFO of Polyphor
Research & Development
New hope against antibiotic resistance: Outer-Membrane Protein Targeting Antibiotics
OMPTA platform could bring further new important therapies in the treatment of Gram-negative pathogens
Recruitment
Debra Barker appointed as new CMDO of Polyphor
Polyphor has announced the appointment of Dr Debra Barker, MD and MSc, to the role of Chief Medical and Development Officer (CMDO)
Research & Development
Polyphor appoints Michael Altorfer as Chief Executive
He replaces Jean-Pierre Obrecht, who will continue as a member of the Board of Directors
Research & Development
Roche signs licensing agreement with Polyphor to combat multi-drug resistant infections
Makes an upfront payment of CHF35m to Polyphor in deal that could be worth up to CHF500m
Research & Development
Polyphor signs MacroFinder collaboration with Boehringer Ingelheim
Will use technology to identify drug candidates addressing therapeutic targets chosen by BI
Subscribe now